-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Immuneering, Maintains $9 Price Target

Benzinga·06/18/2025 11:49:11
Listen to the news
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $9 price target.